natgillin/translations-raw huggingface dataset:
Effects of posaconazole on other medicinal products 
Vplivi posakonazola na druga zdravila
In Study 316, overall mortality was similar (POS, 25%; FLU, 28%); however, the proportion of IFI- related deaths was significantly lower in the POS group (4/301) compared with the FLU group (12/299; P= 0.0413). 
V študiji 316 je bila celokupna umrljivost podobna (POS 25 %, FLU 28%),vendar je bil odstotek zinvazivno glivno okužbo povezanih smrti v skupini s POS značilno manjši (4/301) kot v skupini sFLU (12/299, p = 0,0413).
If you are a woman who could become pregnant you should use effective contraception while you are taking this medicine. 
Če ste ženska v rodni dobi, morate med jemanjem tega zdravila uporabljati učinkovito kontracepcijo.
Reproduction, peri- and postnatal development studies were conducted in rats. 
Pri podganah so bile opravljene študije razmnoževanja ter peri-in post-natalnega razvoja.
See “Other medicines and Posaconazole Accord” below for more information including information on other medicines which may interact with Posaconazole Accord. 
Glejte "Druga zdravila in zdravilo Posakonazol Accord" (spodaj) za več informacij, vključno z informacijami o drugih zdravilih, ki lahko medsebojno delujejo z zdravilom Posakonazol Accord.
No data are available for the tablet formulation. 
Podatkov za zdravilo v obliki tablet ni na voljo.
No pharmacokinetic data are available from paediatric patients less than 8 years of age. 
Farmakokinetičnih podatkov za pediatrične bolnike, mlajše od 8let, ni na voljo.
Five of these patients had chromoblastomycosis due to Fonsecaea pedrosoi and 4 had mycetoma, mostly due to Madurella species. 
Pet od teh bolnikov je imelo kromoblastomikozo zaradi okužbe sFonsecaea pedrosoi, 4 pasoimelimicetom, večinoma zaradi okužbe zMadurella spp.
Endocrine disorders Rare: 
Bolezni endokrinega sistema Redki:
pulmonary hypertension, interstitial pneumonia, pneumonitis 
pljučna hipertenzija, intersticijska pljučnica, pnevmonitis
The safety of posaconazole tablet has been assessed in 336 patients and healthy volunteers enrolled in clinical trials. 
Varnost tablet posakonazola so ocenili pri 336 bolnikih in zdravih prostovoljcih, vključenih v klinična preskušanja.
For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with Posaconazole Accord should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm3. 
Pri bolnikih z akutno mieloično levkemijo ali mielodisplastičnimi sindromi je treba profilakso z zdravilom Posakonazol Accord začeti več dni pred pričakovanim pojavom nevtropenije in naj traja še 7 dni po zvečanjuštevila nevtrofilcev nad 500 celic/mm3.
Please make sure you tell your doctor about all the medicines you are taking (prescribed or non-prescribed). 
Zdravniku morate zato povedati za vsa zdravila, ki jih jemljete (tako za zdravila, ki ste jih dobili na recept, kot za takšna, ki ste jih dobili brez recepta).
Posaconazole must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus. 
Posakonazola sene sme uporabljatipri nosečnicah, razen če korist za mater očitno odtehta možno tveganje za plod.
Among eighteen patients who were intolerant or had infections refractory to amphotericin B or itraconazole, seven patients were classed as responders. 
Med osemnajstimi bolniki, ki niso prenašaliamfotericina B ali itrakonazola ali ki so imeli okužbe, odporne na amfotericin B ali itrakonazol, so jih sedem uvrstili med odzivne na zdravljenje.
Prophylaxis of Invasive Fungal Infections (IFIs) (Studies 316 and 1899) Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections. 
Profilaksa invazivnih glivnih okužb (študiji 316 in 1899) Opravljeni sta bili dve randomizirani, kontrolirani študiji profilakse pri bolnikih z velikim tveganjem za pojav invazivnih glivnih okužb.
You may need to have blood tests while you are taking this medicine. 
Morda vam bodo morali med jemanjem tega zdravilaopravljati preiskave krvi.
There is insufficient information on the use of posaconazole in pregnant women. 
O uporabi posakonazola pri nosečnicah ni dovolj podatkov.
Triplex (PVC/PE/PVdC) white opaque-aluminium blister or perforated unit dose blister in cartons of 24 or 96 tablets. 
Bel neprozoren-aluminijev pretisni omot tripleks (PVC/PE/PVdC) ali perforiran pretisni omot v škatlah, ki vsebujejo po 24 ali 96 tablet.
Laboratori Fundacio Dau C/ C, 12-14 Pol. Ind. Zona Franca, Barcelona, 08040, Spain 
Laboratori Fundació Dau C/ C, 12-14 Pol. Ind. Zona Franca, Barcelona, 08040, Španija
Most of the vinca alkaloids (e.g., vincristine and vinblastine) are substrates of CYP3A4. 
Večina alkaloidov vinke (npr. vinkristin in vinblastin) je substratov CYP3A4.
Clinical isolates with decreased susceptibility to posaconazole have been identified. 
Našli so klinične izolate z zmanjšano občutljivostjo za posakonazol.
The effect of posaconazole on CYP3A4 substrates in patients might be somewhat lower than that observed in healthy volunteers, and is expected to be variable between patients due to the variable posaconazole exposure in patients. 
Učinek posakonazola na substrate CYP3A4 je lahkopri bolnikih nekoliko manjši kot pri zdravih prostovoljcih in mogoče je pričakovati, da se od bolnika do bolnika razlikuje zaradi različne stopnje izpostavljenosti posakonazolu.
The subject population included: 1) patients with AML or MDS who had recently received chemotherapy and had developed or were anticipated to develop significant neutropenia, or 2) patients who had undergone a HSCT and were receiving immunosuppressive therapy for prevention or treatment of GVHD. 
Populacija preiskovancev je vključevala: 1) bolnike z AML ali MDS, ki so nedavno prejemali kemoterapijo in se jim je pojavila, ali je bilo pričakovano, da se jim bo pojavila pomembna nevtropenija, oziroma 2) bolnike, ki so imeli opravljeno presaditev hematopoetskih matičnih celic (HSCT) in so prejemali imunosupresivno zdravljenje za preprečevanje ali zdravljenje GVHD.
It is recommended to exercise caution due to the potential for higher plasma exposure. 
Priporočljiva je previdnostzaradi možne večje plazemske izpostavljenosti.
TreatmentInvasive Aspergillosis Study 0041 
Zdravljenjeinvazivnaasp ergiloza Študija 0041
Results from clinical studies in prophylaxis of Invasive Fungal Infections Study 
Preglednica 5.Izsledki kliničnih študij profilakse invazivnih glivnih okužb Študija
If you are already taking rifabutin, you will need a blood test and you will need to look out for some possible side effects of rifabutin. 
boste morali opraviti preiskavo krvi in biti pozorni na nekatere možne neželene učinke rifabutina.
liver function tests raised (ALT increased, AST increased, bilirubin increased, alkaline phosphatase increased, GGT increased) 
zvišane vrednosti jetrnih testov (zvišanje ALT, zvišanje AST, zvišanje bilirubina, zvišanje alkalne fosfataze, zvišanje GGT)
This medicine works by killing or stopping the growth of some types of fungi that can cause infections. 
To zdravilo deluje tako, da uniči nekatere vrste gliv, ki lahko povzročajo okužbe, ali ustavi njihovo rast.
Administration of other azoles has been associated with increases in digoxin levels. 
Uporaba drugih azolov je bila povezana s povečanjem koncentracij digoksina.
Do not adapt your dose yourself before consulting your doctor or change your treatment regimen. 
Ne prilagajajte odmerka in ne spreminjajte sheme svojega zdravljenja, ne da bi se prej posvetovali z zdravnikom.
Posaconazole tablets are the preferred formulation to optimize plasma concentrations and generally provide higher plasma drug exposures than posaconazole oral suspension. 
Posakonazol v obliki tablet je primernejša oblika za optimiziranje plazemske koncentracije in na splošno zagotavlja večjo plazemsko izpostavljenost zdravilu kot peroralna suspenzija posakonazola.
Cav Range (ng/mL) 
Razpon Cav(ng/m
The safety of posaconazole tablets has been assessed in 230 patients enrolled in the pivotal clinical study. 
Varnost tablet posakonazola so ocenili pri 230 bolnikih, vključenih v ključno klinično študijo.
There is no information regarding cross-sensitivity between posaconazole and other azole antifungal agents. 
O navzkrižni občutljivosti med posakonazolom in drugimi azolskimi antimikotiki ni podatkov.
Based on pharmacokinetic data in 10 of these paediatric patients, the pharmacokinetic profile appears to be similar to patients ≥ 18 years of age. 
Na podlagi farmakokinetičnih podatkov pri 10 od teh pediatričnih bolnikovjefarmakokinetičniprofil videtipodoben kot pri bolnikih, starih ≥18 let.
In Study 1899, a significant decrease in all cause mortality in favour of posaconazole was observed [POS 49/304 (16%) vs. FLU/ITZ 67/298 (22%) p= 0.048]. 
V študiji 1899 so značilno manjšo celokupno umrljivost zaradi vseh vzrokovopazili v skupini, ki je prejemala posakonazol [POS 49/304 (16 %) v primerjavi s FLU/ITZ67/298 (22 %), p = 0,048].
The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown. 
Vpliv posakonazola na koncentracijo fosamprenavirja v primeru uporabe fosamprenavirja z ritonavirjem ni znan.
HIV Protease inhibitors 
Zaviralci proteaze HIV
abnormal dreams, confusional state, sleep disorder 
nenormalne sanje, zmedenost, motnje spanja
Posaconazole Accord can increase the amount of these medicines in the blood which may lead to a severe decrease in blood flow to your fingers or toes and could cause damage to them. 
Zdravilo Posakonazol Accord lahko poveča koncentracijo teh zdravil v krvi; to lahko zelo zmanjša dotok krvi v prste rok in nog in lahko povzroči njihovo okvaro.
In twelve-month neurotoxicity studies in dogs and monkeys, no functional effects were observed on the central or peripheral nervous systems at systemic exposures greater than those achieved therapeutically. 
V 12-mesečnih študijahnevrotoksičnosti na psih in opicah niso opažali funkcionalnih učinkov na osrednje ali periferno živčevje pri sistemskih izpostavljenostih, ki so bile večje od terapevtsko doseženih izpostavljenosti.
During post-marketing surveillance of posaconazole oral suspension, severe hepatic injury with fatal outcome has been reported (see section 4.4). 
Med spremljanjem v obdobju trženja peroralne suspenzije posakonazola so poročali o hudi okvari jeter s smrtnim izidom (glejte poglavje 4.4).
Prophylaxis in Neutropenia Study 1899 
Profilaksapri nevtropeniji Študija 1899
Posaconazole has been shown in vitro to be active against the following microorganisms: Aspergillus species (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus. 
Dokazanoje,daposakonazol invitro delujeprotinaslednjimmikroorganizmom:vrstiAspergillus(Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), vrstiCandida (Candidaalbicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaeapedrosoi, in vrstamFusarium, Rhizomucor, Mucor in Rhizopus.
- some medicines used to treat or prevent fits including; phenytoin, carbamazepine, phenobarbital or primidone). 
- nekatera zdravila, ki se uporabljajo za zdravljenje ali preprečevanje epileptičnih napadov, med njimi fenitoin, karbamazepin, fenobarbital ali primidon.
200 mg three times daily 
200 mg trikrat nadan
acute renal failure, renal failure, blood creatinine increased 
akutna odpoved ledvic, odpoved ledvic, zvišanje ravni kreatinina v krvi
There is no clinical experience assessing the impact of posaconazole on fertility in humans. 
Kliničnih izkušenj glede vpliva posakonazola na plodnost pri človeku ni.
Co-administration may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes (see section 4.3). 
Sočasna uporaba lahko povzroči povečanje koncentracije teh zdravilv plazmi, kar vodi do podaljšanja intervala QTc in v redkih primerih povzročitorsades de pointes(glejte poglavje 4.3).
Posaconazole, after administration of the tablet, has a mean apparent volume of distribution of 394 L (42%), ranging between 294-583 L among the studies in healthy volunteers. 
Po uporabi tablet je povprečni navidezni volumen porazdelitve posakonazola 394 l (42 %) in v študijah pri zdravih prostovoljcih sega od 294 do 583 l.
Increased systolic and arterial blood pressures (up to 29 mm-Hg) were seen in rats and monkeys at systemic exposures 2.1-fold and 8.5-fold greater, respectively, than those achieved with the human therapeutic doses. 
Zvišan sistolični in arterijski krvni tlak (do 29 mmHg) so opažali pri podganah oz. opicah pri sistemskih izpostavljenostih, ki so bile 2,1-krat oz. 8,5-krat večje od izpostavljenosti,
Patients, in particular those receiving posaconazole after HSCT, who have a low body weight (< 60 kg) are more likely to experience higher plasma concentrations of posaconazole and should be closely monitored for adverse events. 
Bolniki, zlasti tisti, ki prejemajo posakonazol po presaditvi hematopoetskih celic in imajo majhnotelesno maso (< 60 kg), imajo večjo verjetnost za povečane koncentracije posakonazola vplazmi injihjetreba skrbno spremljati glede neželenih učinkov.
The mean duration of therapy was 29 days for posaconazole and 25 days for fluconazole/itraconazole. 
Zdravljenje s posakonazolom jetrajalopovprečno29 dni in s flukonazolom/itrakonazolom 25 dni.
Limited data on the effect of hepatic impairment (including Child-Pugh C classification of chronic liver disease) on the pharmacokinetics of posaconazole demonstrate an increase in plasma exposure compared to subjects with normal hepatic function, but do not suggest that dose adjustment is necessary (see sections 4.4 and 5.2). 
Majhno število podatkov o vplivu okvare jeter (vključno s kronično boleznijo jeter razreda C po klasifikacijiChild-Pugh) na farmakokinetiko posakonazola kaže na povečanje plazemskeizpostavljenosti temu zdravilu v primerjavi s preiskovanci z normalnim delovanjem jeter, vendar nenakazuje, da bi bilo treba prilagoditiodmerek (glejte poglavji 4.4 in 5.2).
Yellow coated, capsule shaped tablet of approximate 17.5 mm length and 6.7 mm width, debossed with “100P” on one side and plain on the other side. 
Rumena obložena tableta v obliki kapsule, dolga približno 17,5mm in široka približno 6,7 mm, z vtisnjeno oznako "100P" na eni strani in brez oznake na drugi strani.
After administration of 14C-posaconazole, radioactivity was predominantly recovered in the faeces (77% of the radiolabelled dose) with the major component being parent compound (66% of the radiolabelled dose). 
Po uporabi14C-posakonazolase jeradioaktivnost pojavila predvsem v blatu (77 %radioaktivno označenega odmerka);glavnideltega jebilamatična spojina (66 % radioaktivno označenega odmerka).
Patients who have severe diarrhoea or vomiting should be monitored closely for breakthrough fungal infections. 
Bolnike, ki imajo hudo drisko ali bruhajo, je treba skrbno spremljati gledeprebijajočih(breakthrough) glivnih okužb.
Treatment should be initiated by a physician experienced in the management of fungal infections or in the supportive care in the high risk patients for which posaconazole is indicated as prophylaxis. 
Zdravljenje mora uvesti zdravnik z izkušnjami pri zdravljenju glivnih okužb ali podporni oskrbi bolnikov z velikim tveganjem, pri katerih je posakonazol indiciran za profilakso.
Supportive care may be considered. 
V poštev pride podporno zdravljenje.
Gender The pharmacokinetics of posaconazole tablets are comparable in men and women. 
Spol Farmakokinetika tablet posakonazola je pri moških in ženskah primerljiva.
Posaconazole tablets are absorbed with a median Tmax of 4 to 5 hours and exhibits dose proportional pharmacokinetics after single and multiple dosing up to 300 mg. 
Tableteposakonazola se absorbirajo s srednjo vrednostjo tmaxod 4 do 5 ur in imajopo enkratnem invečkratnih odmerkih do 300 mg odmerku sorazmerno farmakokinetiko.
adrenal insufficiency, blood gonadotropin decreased 
insuficienca nadledvične žleze, znižana raven gonadotropinov v krvi
300 mg once daily (Day 1 300 mg twice daily)* 
300 mg enkrat na dan (1. dan300mg dvakrat na dan)*
- a “statin” such as simvastatin, atorvastatin or lovastatin used to treat high cholesterol. 
- katerega od statinov, na primer simvastatina, atorvastatina ali lovastatina, ki se uporabljajo za zdravljenje visokega holesterola.
Pharmacokinetic modeling with an oral tablet formulation suggests that patients weighing greater than 120 kg may have lower posaconazole exposure. 
Farmakokinetično modeliranje z obliko peroralnih tablet kaže, da je lahko izpostavljenost posakonazolumanjša pri bolnikih, ki tehtajo več kot 120 kg.
electrolyte imbalance, anorexia, decreased appetite, hypokalaemia, hypomagnesaemia 
neravnovesje elektrolitov, anoreksija, zmanjšanje apetita, hipokaliemija, hipomagneziemija
It is particularly important to try to ensure that maximal plasma levels are achieved in patients infected with Aspergillus (see sections 4.2 and 5.2 on recommended dose regimens). 
da pri bolnikih, okuženih zAspergillusom,dosežemonajvečje plazemske koncentracije (glejte poglavji 4.2 in 5.2 o priporočenih režimih odmerjanja).
Sulfonylureas 
Sulfonilsečnine
An effect of renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended (see section 5.2). 
Vpliva okvare ledvic na farmakokinetiko posakonazola ni pričakovati, zato prilagajanje odmerkov nipotrebno (glejte poglavje 5.2).
Therefore, posaconazole may increase plasma concentration of digoxin and digoxin levels need to be monitored when initiating or discontinuing posaconazole treatment. 
Posakonazol torej lahko poveča plazemsko koncentracijo digoksina, zato je treba ob uvedbi in po prenehanju zdravljenja s posakonazolom spremljati koncentracijo digoksina.
No clinically relevant changes in the mean QTc (Fridericia) interval from baseline were observed. 
V primerjavi z izhodiščem niso opazili kliničnopomembnih sprememb povprečnega intervala QTc (Fridericia).
Additionally, twelve patients 13-17 years of age received posaconazole oral suspension 600 mg/day for prophylaxis of invasive fungal infections (Studies 316 and 1899). 
Poleg tega je dvanajst bolnikov, starih od 13 do 17 let, prejemalo peroralno suspenzijo posakonazola v odmerku 600mg/danzaprofilaksoinvazivnihglivnihokužb(študiji316in1899).
Posaconazole Accord must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval (see sections 4.3 and 4.5). 
Zdravila Posakonazol Accord se ne sme uporabljati skupaj z zdravili, ki so substrati CYP3A4 in za katere je znano, da podaljšajo interval QTc (glejte poglavji 4.3 in 4.5).
Posaconazole increased the Cmax and AUC of rifabutin by 31% and 72%, respectively. 
Posakonazolje povečal Cmaxrifabutina za 31% in AUC rifabutina za 72%.
If these medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended. 
V primeru sočasne uporabe je priporočljivo skrbno spremljanje celotne krvne slike in neželenih učinkov, povezanih s povečanokoncentracijo rifabutina (npr. uveitisa).
If you forget to take Posaconazole Accord - If you forget a dose, take it as soon as you remember it. - However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. 
Če ste pozabili vzeti zdravilo Posakonazol Accord - Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite.
200 mg four times daily (hospitalized) then 400 mg twice daily 
200 mg štirikratnadan(h ospitalizirani), nato 400 mg dvakrat na dan
The safety profile in these patients < 18 years of age appears similar to the safety profile observed in adults. 
Varnostniprofilzdravila je pri teh bolnikih, mlajših od 18 let, videti podoben kot pri odraslih.
Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). 
Sočasni uporabiposakonazola in rifabutina se je treba izogibati, razen če korist za bolnika odtehta tveganje (glejtezgoraj za učinke rifabutina na plazemsko koncentracijo posakonazola).
INFORMATION IN BRAILLE Posaconazole Accord 100 mg 
PODATKI V BRAILLOVI PISAVI Posakonazol Accord 100 mg
Midazolam and other benzodiazepines metabolised by CYP3A4 
Midazolam in drugi benzodiazepini, ki se presnovijo s CYP3A4
In heart transplant patients on stable doses of ciclosporin, posaconazole oral suspension 200 mg once daily increased ciclosporin concentrations requiring dose reductions. 
Pri bolnikih s presajenim srcem, ki prejemajo stabilne odmerke ciklosporina, je peroralna suspenzija posakonazola v odmerku 200 mg enkrat na dan povečala koncentracijo ciklosporina, tako da je bilopotrebno zmanjšanje njegovega odmerka.
The safety profile of tablets was similar to that of the oral suspension. 
Varnostni profil tablet je podoben varnostnemu profilu peroralne suspenzije.
Co-administration with ergot alkaloids (see section 4.5). 
Sočasna uporaba z alkaloidi ergot (glejte poglavje 4.5).
Patients who develop abnormal liver function tests during Posaconazole Accord therapy must be routinely monitored for the development of more severe hepatic injury. 
Bolnike, pri katerih se med zdravljenjem z zdravilom Posakonazol Accord pojavijo nenormalni izvidi jetrnihtestov, je treba rutinsko spremljati glede nastanka hujše poškodbe jeter.
Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. 
Sočasna uporaba fosamprenavirja in posakonazola lahko zmanjša koncentracijo posakonazola vplazmi.
Currently available data are described in sections 5.1 and 5.2, but no recommendation on a posology can be made. 
Varnost in učinkovitost posakonazola pri otrocih, mlajših od 18 let, nistaugotovljeni.Trenutnorazpoložljivi podatki so opisani v poglavjih 5.1 in 5.2, vendar priporočil o odmerjanju ni mogoče dati.
Look at the list of medicines given above that must not be taken while you are taking Posaconazole Accord. 
Preberite zgornji seznam zdravil, ki jih ne smete jemati med zdravljenjem z zdravilom Posakonazol Accord.
In addition to the medicines named above there are other medicines that carry a risk of rhythm problems that may be greater when they are taken with Posaconazole Accord. 
Poleg zgoraj navedenih zdravil so s tveganjem za motnje srčnega ritma povezana še druga zdravila in tveganje je lahko večje, če takšna zdravila jemljete skupaj z zdravilom Posakonazol
Posaconazole Accord may possibly increase the risk of side effects of some other medicines by increasing the amount of these medicines in the blood. 
Zdravilo Posakonazol Accord morda lahko poveča tveganje za pojav neželenih učinkov nekaterih drugih zdravil, ker poveča njihovo količino v krvi.
blurred vision, photophobia, visual acuity reduced 
zamegljen vid, fotofobija, zmanjšanje ostrine vida
Posaconazole should be used with caution in patients with hepatic impairment due to limited clinical experience and the possibility that posaconazole plasma levels may be higher in these patients (see sections 4.2 and 5.2). 
Pri bolnikih z okvaro jeter je treba posakonazol uporabljati previdno, ker jekliničnih izkušenj malo inker obstaja možnost, da je koncentracija posakonazola v plazmi pri teh bolnikih višja (glejte poglavji 4.2 in 5.2).
Controla Proportion (%) of patients with proven/probable Aspergillosis On-treatment period b 
Kontrolnaskupinaa Odstotek (%) bolnikov zdokazano oziroma verjetno aspergilozo Obdobjezdravljenjab
Monitoring of glucose concentrations is recommended in diabetic patients. 
Pri sladkornih bolnikih je priporočljivo spremljati koncentracije glukoze.